Cantor Fitzgerald Initiates Coverage on Inventiva (NASDAQ:IVA)

Research analysts at Cantor Fitzgerald assumed coverage on shares of Inventiva (NASDAQ:IVA) in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage set an “overweight” rating on the stock.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Truist Financial assumed coverage on Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Performance

Inventiva stock opened at $4.52 on Friday. Inventiva has a 1 year low of $2.85 and a 1 year high of $7.98. The firm’s 50-day moving average is $4.37 and its 200-day moving average is $5.32.

Institutional Trading of Inventiva

Large investors have recently modified their holdings of the company. Creative Planning bought a new stake in Inventiva in the 2nd quarter valued at about $32,000. Virtu Financial LLC bought a new position in Inventiva in the 4th quarter worth about $60,000. XTX Topco Ltd bought a new position in Inventiva in the 4th quarter worth about $84,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the third quarter valued at approximately $116,000. Finally, Cerity Partners LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at approximately $93,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.